Streetbeat News

Regulatory

PRTC

PureTech Health has initiated a Phase 2A proof-of-concept trial of LYT-300 (oral allopregnanolone) in healthy volunteers using a validated clinical model of anxiety. Results are expected by the end of 2023. A Phase 2A trial in patients with postpartum depression is planned to start in 2H 2023.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:15 am

FDX

KBH

LI

LZB

NIO

PDCO

QQQ

SCS

SPY

WGO

XPEV

US stocks are expected to have a cautious start on Wednesday as traders anticipate Federal Reserve Chair Jerome Powell's Congressional testimony. FedEx Corp.'s disappointing guidance may cause anxiety about the economy. Chinese EV startups Nio, XPeng, and Li Auto rally after China extends green-energy vehicle incentives.

Portfolio Pulse from Shanthi Rexaline

June 21, 2023 | 11:11 am

XERS

Xeris Biopharma has announced the dosing of the first participant in a Phase 2 clinical study of its investigational subcutaneous levothyroxine (XP-8121) for patients with hypothyroidism.

Portfolio Pulse from Bill Haddad

June 21, 2023 | 11:11 am

CMMB

Chemomab Therapeutics reports positive data from a secondary analysis of its Phase 2a liver fibrosis trial in NASH patients, showing that treatment with CM-101 improves additional biomarkers of fibrosis and inflammation, reinforcing and extending initial study results.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:08 am

QURE

uniQure announces interim data from Phase I/II trial of AMT-130 in Huntington's disease, showing preserved function and clinical benefits compared to the disease's natural history. The data supports continuing clinical development and pursuing regulatory interactions for late-stage development.

Portfolio Pulse from Bill Haddad

June 21, 2023 | 11:08 am

BLUE

bluebird bio announced that the FDA has granted priority review for its Biologics License Application (BLA) for lovotibeglogene autotemcel (lovo-cel) in patients with sickle cell disease aged 12 years and older with a history of vaso-occlusive events.

Portfolio Pulse from Bill Haddad

June 21, 2023 | 11:06 am

AZN

PIRS

AstraZeneca has discontinued the Phase 2a trial of Elarekibep (PRS-060/AZD1402) due to new non-clinical safety findings from a 13-week toxicology study. Pieris will review the implications of the data and AstraZeneca's decision before providing further updates.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:04 am

ATVI

MSFT

Microsoft is preparing to defend its acquisition of Activision Blizzard against the US Federal Trade Commission's (FTC) attempt to block the deal. Top executives, including Microsoft CEO Satya Nadella and Activision Blizzard CEO Bobby Kotick, will appear in court to argue against the FTC's concerns about consumer choice and competition.

Portfolio Pulse from Rounak Jain

June 21, 2023 | 10:44 am

WMT

Walmart and its subsidiary Sam's Club have announced stricter standards for their tuna supply chains to combat illegal fishing and protect the ocean ecosystem. The new standards require tuna suppliers to source only from vessels with 100% monitoring and fisheries using zero high seas transshipment.

Portfolio Pulse from Benzinga Newsbot

June 21, 2023 | 10:41 am

FXI

SPY

China has expressed anger after President Biden referred to President Xi Jinping as a 'dictator' in a recent interview. This could potentially strain the US-China relationship and impact the stock market.

Portfolio Pulse from Charles Gross

June 21, 2023 | 10:33 am